Novo Nordisk’s Zenagamtide shows strong HbA1c and weight loss benefits in phase II trial
Novo Nordisk has announced positive Phase II results for zenagamtide, an investigational once-weekly subcutaneous therapy for adults with…
Awiqli® approved in the US, the first and
Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type…